The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
- Author
- ReachMD
- Published
- Tue 17 Dec 2024
- Episode Link
- http://reachmd.com/programs/cme/the-changing-paradigm-of-treating-masldmash-at-the-crossroads-of-hepato-cardiometabolic-care-chairs-perspective/26372/
CME credits: 0.25
Valid until: 17-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-changing-paradigm-of-treating-masldmash-at-the-crossroads-of-hepato-cardiometabolic-care-chairs-perspective/26372/
Valid until: 17-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-changing-paradigm-of-treating-masldmash-at-the-crossroads-of-hepato-cardiometabolic-care-chairs-perspective/26372/
MASLD/MASH is a serious, chronic, progressive disease that will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Do you know how to effectively treat MASLD/MASH in your patients, and are you familiar with drugs currently in development? Tune in for an overview of the latest data.
=